Search research articles
Contact Us
Filters
Showing results (301-310 of 315) with videos related to
Page
of 32
Sort By:
The Oncologist
|
February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
Neal D Shore, Christian Gratzke, Susan Feyerabend, et al.
JAMA
|
March 23, 2025
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
Adam Kinnaird, Ferdinand Luger, Hannes Cash, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Neal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
The Journal of Urology
|
April 28, 2026
External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial
Alon Lazarovich, Melis Guer, Ferdinand Luger, et al.
BJU International
|
September 9, 2022
Low-grade prostate cancer should still be labelled cancer
Kenneth A Iczkowski, Mariel Molina, Lars Egevad, et al.
European Urology
|
December 3, 2014
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer
Dipen J Parekh, Sanoj Punnen, Daniel D Sjoberg, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Nature Communications
|
December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
Soumyajit Roy, Yilun Sun, Maha Hussain, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
Page
of 32
Search research articles
Search
Showing results (301-310 of 315) with videos related to
Sort By:
Page
of 32
The Oncologist
|
February 23, 2024
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
Neal D Shore, Christian Gratzke, Susan Feyerabend, et al.
JAMA
|
March 23, 2025
Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial
Adam Kinnaird, Ferdinand Luger, Hannes Cash, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study
Neal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
The Journal of Urology
|
April 28, 2026
External Validation of the PRI-MUS Scoring System: A Secondary Analysis of the OPTIMUM Randomized Controlled Trial
Alon Lazarovich, Melis Guer, Ferdinand Luger, et al.
BJU International
|
September 9, 2022
Low-grade prostate cancer should still be labelled cancer
Kenneth A Iczkowski, Mariel Molina, Lars Egevad, et al.
European Urology
|
December 3, 2014
A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer
Dipen J Parekh, Sanoj Punnen, Daniel D Sjoberg, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Nature Communications
|
December 16, 2025
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer
Soumyajit Roy, Yilun Sun, Maha Hussain, et al.
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
Page
of 32